Telix Pharmaceuticals Appoints Two New Directors
Analysis based on 9 articles · First reported Apr 08, 2026 · Last updated Apr 08, 2026
The appointments of Maria Rivas and William Jellison to the Telix Pharmaceuticals Limited board are expected to positively impact the company's governance and strategic direction, potentially leading to increased investor confidence. Their extensive experience in the pharmaceutical and finance sectors should enhance Telix's capabilities as it expands globally.
Telix Pharmaceuticals Limited announced the appointment of two new Non-Executive Directors, Maria Rivas, MD, and William Jellison, effective May 11, 2026. These appointments are part of Telix's Board expansion and succession planning, aiming to strengthen the company's governance, financial oversight, and clinical leadership. Maria Rivas brings over 25 years of experience in late-stage clinical development, commercialization, and governance, including her role as Chief Medical Officer at Pfizer, Inc. William Jellison offers over 30 years of experience in corporate finance, including audit committee leadership and his tenure as Vice President and CFO of Stryker Corporation. The Interim Chair, Mark Nelson, stated that these additions, along with David Gill, align with Telix's evolution as a dual-listed, global, commercial-stage biopharmaceutical company.
Set up alerts, explore entity relationships, search across thousands of events, and build custom intelligence feeds.
Open Dashboard